



Combination Therapy for the Treatment of Immune Checkpoint Blockade Resistant Cancers

WARF: P250217US02

Inventors: Deric Wheeler, Bridget Crossman, Ravi Salgia

The Invention

UW-Madison researchers in collaboration with a researcher at City of Hope Cancer Center developed a combination therapy that utilizes Keytruda and a clinically approved receptor tyrosine kinase inhibitor to treat cancer. They showed that dosed separately, neither Keytruda nor the kinase inhibitor stopped tumor growth in a model for head and neck cancer. However, when given together, the two treatments displayed a dramatic effect on tumor growth.

Tech Fields

- [Therapeutics & Vaccines : Oncology](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847